Skip to content
Screener

BridgeBio Pharma BBIO Royalty revenue — Revenue

Other product segments

Cost of license, services, and royalty revenue
$10.3M—
License and services revenue
$4.42M—

Similar metrics at other companies

Lantheus Holdings logo
LNTHLicenseand Royalty Revenues — Revenue
$11.25M+222%
Nuvation Bio logo
NUVBRoyalty Revenue — Revenue
$1.6M+700%
TEC
TECHRoyalty — Revenue
$4.97M-1.4%
Abercrombie & Fitch logo
ANFRoyalty — Revenue
$15.75M+2.9%
Axsome Therapeutics logo
AXSMRoyalty — Revenue
$4.07M+269%
Opko Health logo
OPKRoyalty — Revenue
$6.4M+4.9%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$16.06B+87.5%
Enterprise value$18.44B+136%
P/S27.7×-8.6×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity2×—
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001743881-26-000019
Line itemThree Months Ended March 31, 20262025
Revenues:
Net product revenue$180,596$36,739
License and services revenue4,41979,690
Royalty revenue9,500204
Total revenues, net194,515116,633
Operating costs and expenses:
Cost of revenues:
Cost of goods sold7,7322,034

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's royalty revenue — revenue?
BridgeBio Pharma (BBIO) reported royalty revenue — revenue of $9.5M in Q1 2026.
How has BridgeBio Pharma's royalty revenue — revenue changed year-over-year?
BridgeBio Pharma's royalty revenue — revenue increased by 4556.9% year-over-year, from $204K to $9.5M.
What does royalty revenue — revenue mean?
This metric represents the income generated from licensing intellectual property or proprietary technology to third-party partners. It reflects the commercialization success of the company's research and development pipeline through external distribution channels. This revenue stream is typically derived from contractual agreements where the company receives a percentage of net sales from products developed using its licensed assets.

Ask your AI about BridgeBio Pharma's royalty revenue — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude